A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
<h4>Background</h4>There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. The aim of this study was to determine the impact of long-term treatment with neuroleptic...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/119aea6129014cfcb7554b21bfb5278c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:119aea6129014cfcb7554b21bfb5278c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:119aea6129014cfcb7554b21bfb5278c2021-11-25T05:37:00ZA randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).1549-12771549-167610.1371/journal.pmed.0050076https://doaj.org/article/119aea6129014cfcb7554b21bfb5278c2008-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18384230/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. The aim of this study was to determine the impact of long-term treatment with neuroleptic agents upon global cognitive decline and neuropsychiatric symptoms in patients with Alzheimer disease.<h4>Methods and findings</h4><h4>Design</h4>Randomised, blinded, placebo-controlled parallel two-group treatment discontinuation trial.<h4>Setting</h4>Oxfordshire, Newcastle and Gateshead, London and Edinburgh, United Kingdom.<h4>Participants</h4>Patients currently prescribed the neuroleptics thioridazine, chlorpromazine, haloperidol trifluoperazine or risperidone for behavioural or psychiatric disturbance in dementia for at least 3 mo.<h4>Interventions</h4>Continue neuroleptic treatment for 12 mo or switch to an identical placebo.<h4>Outcome measures</h4>Primary outcome was total Severe Impairment Battery (SIB) score. Neuropsychiatric symptoms were evaluated with the Neuropsychiatric Inventory (NPI).<h4>Results</h4>165 patients were randomised (83 to continue treatment and 82 to placebo, i.e., discontinue treatment), of whom 128 (78%) commenced treatment (64 continue/64 placebo). Of those, 26 were lost to follow-up (13 per arm), resulting in 51 patients per arm analysed for the primary outcome. There was no significant difference between the continue treatment and placebo groups in the estimated mean change in SIB scores between baseline and 6 mo; estimated mean difference in deterioration (favouring placebo) -0.4 (95% confidence interval [CI] -6.4 to 5.5), adjusted for baseline value (p = 0.9). For neuropsychiatric symptoms, there was no significant difference between the continue treatment and placebo groups (n = 56 and 53, respectively) in the estimated mean change in NPI scores between baseline and 6 mo; estimated mean difference in deterioration (favouring continue treatment) -2.4 (95% CI -8.2 to 3.5), adjusted for baseline value (p = 0.4). Both results became more pronounced at 12 mo. There was some evidence to suggest that those patients with initial NPI >/= 15 benefited on neuropsychiatric symptoms from continuing treatment.<h4>Conclusions</h4>For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this benefit must be weighed against the side effects of therapy.<h4>Trial registration</h4>Cochrane Central Registry of Controlled Trials/National Research Register (#ISRCTN33368770).Clive BallardMarisa Margallo LanaMegan TheodoulouSimon DouglasRupert McShaneRobin JacobyKatja KossakowskiLy-Mee YuEdmund JuszczakInvestigators DART ADPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 5, Iss 4, p e76 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Clive Ballard Marisa Margallo Lana Megan Theodoulou Simon Douglas Rupert McShane Robin Jacoby Katja Kossakowski Ly-Mee Yu Edmund Juszczak Investigators DART AD A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| description |
<h4>Background</h4>There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. The aim of this study was to determine the impact of long-term treatment with neuroleptic agents upon global cognitive decline and neuropsychiatric symptoms in patients with Alzheimer disease.<h4>Methods and findings</h4><h4>Design</h4>Randomised, blinded, placebo-controlled parallel two-group treatment discontinuation trial.<h4>Setting</h4>Oxfordshire, Newcastle and Gateshead, London and Edinburgh, United Kingdom.<h4>Participants</h4>Patients currently prescribed the neuroleptics thioridazine, chlorpromazine, haloperidol trifluoperazine or risperidone for behavioural or psychiatric disturbance in dementia for at least 3 mo.<h4>Interventions</h4>Continue neuroleptic treatment for 12 mo or switch to an identical placebo.<h4>Outcome measures</h4>Primary outcome was total Severe Impairment Battery (SIB) score. Neuropsychiatric symptoms were evaluated with the Neuropsychiatric Inventory (NPI).<h4>Results</h4>165 patients were randomised (83 to continue treatment and 82 to placebo, i.e., discontinue treatment), of whom 128 (78%) commenced treatment (64 continue/64 placebo). Of those, 26 were lost to follow-up (13 per arm), resulting in 51 patients per arm analysed for the primary outcome. There was no significant difference between the continue treatment and placebo groups in the estimated mean change in SIB scores between baseline and 6 mo; estimated mean difference in deterioration (favouring placebo) -0.4 (95% confidence interval [CI] -6.4 to 5.5), adjusted for baseline value (p = 0.9). For neuropsychiatric symptoms, there was no significant difference between the continue treatment and placebo groups (n = 56 and 53, respectively) in the estimated mean change in NPI scores between baseline and 6 mo; estimated mean difference in deterioration (favouring continue treatment) -2.4 (95% CI -8.2 to 3.5), adjusted for baseline value (p = 0.4). Both results became more pronounced at 12 mo. There was some evidence to suggest that those patients with initial NPI >/= 15 benefited on neuropsychiatric symptoms from continuing treatment.<h4>Conclusions</h4>For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this benefit must be weighed against the side effects of therapy.<h4>Trial registration</h4>Cochrane Central Registry of Controlled Trials/National Research Register (#ISRCTN33368770). |
| format |
article |
| author |
Clive Ballard Marisa Margallo Lana Megan Theodoulou Simon Douglas Rupert McShane Robin Jacoby Katja Kossakowski Ly-Mee Yu Edmund Juszczak Investigators DART AD |
| author_facet |
Clive Ballard Marisa Margallo Lana Megan Theodoulou Simon Douglas Rupert McShane Robin Jacoby Katja Kossakowski Ly-Mee Yu Edmund Juszczak Investigators DART AD |
| author_sort |
Clive Ballard |
| title |
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| title_short |
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| title_full |
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| title_fullStr |
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| title_full_unstemmed |
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). |
| title_sort |
randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the dart-ad trial). |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2008 |
| url |
https://doaj.org/article/119aea6129014cfcb7554b21bfb5278c |
| work_keys_str_mv |
AT cliveballard arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT marisamargallolana arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT megantheodoulou arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT simondouglas arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT rupertmcshane arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT robinjacoby arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT katjakossakowski arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT lymeeyu arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT edmundjuszczak arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT investigatorsdartad arandomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT cliveballard randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT marisamargallolana randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT megantheodoulou randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT simondouglas randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT rupertmcshane randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT robinjacoby randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT katjakossakowski randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT lymeeyu randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT edmundjuszczak randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial AT investigatorsdartad randomisedblindedplacebocontrolledtrialindementiapatientscontinuingorstoppingneurolepticsthedartadtrial |
| _version_ |
1718414560612843520 |